Press Releases

2024

Freenome Announces CEO Transition
September 25, 2024
Board of Directors Establishes Interim Office of the CEO and Initiates Search for a Successor to Lead Company Through Next Phase of Development and Commercialization ...
Freenome Announces Topline Results for PREEMPT CRC® to Validate the First Version of its Blood-Based Test for the Early Detection of Colorectal Cancer
April 2, 2024
Study met all primary endpoints, including 79.2% sensitivity for colorectal cancer (CRC) and 91.5% specificity for non-advanced colorectal neoplasia PREEMPT CRC, the largest study of ...
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
February 15, 2024
Roche led the financing alongside existing and new investors The funds will progress clinical programs and expand platform capabilities SOUTH SAN FRANCISCO, CA (Feb. 15, ...

2023

Freenome Initiates PROACT LUNG Clinical Study for the Early Detection of Lung Cancer Using Blood Test Developed on Multiomics Platform
December 12, 2023
Registrational study targets enrollment of 20,000 individuals at high risk of lung cancer SOUTH SAN FRANCISCO, CA (Dec. 12, 2023) — Freenome, a privately held ...
Walgreens and Freenome Establish Partnership to Increase Diversity in Research for the Early Detection of Cancer
June 15, 2023
DEERFIELD, Ill. & SAN FRANCISCO, June 15, 2023 — Walgreens and Freenome today announced a multi-year relationship to advance clinical studies of Freenome’s blood-based tests for ...
Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd
May 22, 2023
Acquisition enhances Freenome’s product portfolio, including autoantibody platform with additional biomarkers important in cancer detection Freenome continues growth trajectory toward offering multiple cancer screening tests ...
Freenome Adds University of Chicago as a Partner for its Vallania Study
April 12, 2023
The Vallania Study targets multiple cancers with different care pathways University of Chicago to enroll patients across its diverse network, expanding access to clinical studies ...
Freenome Adds Renown Health as Partner for The Sanderson Study
March 28, 2023
The Sanderson Study is Freenome’s study that pairs real-world data with multiomics for the detection of multiple cancers Renown Health’s William N. Pennington Cancer Institute ...
Freenome Presents a Subject Population Analysis of a Clinical Study Using a Multiomics Blood Test for the Early Detection of Colorectal Cancer
March 6, 2023
PREEMPT CRC is a large, representative registrational study for the early detection of colorectal cancer Findings presented at the Western Colorectal Cancer Consortium Conference SOUTH ...
Freenome Partners with Geisinger for the Sanderson Study
January 18, 2023
The Sanderson Study is Freenome’s clinical study that combines multiomics with real-world data to detect multiple cancers Geisinger to enroll patients across its network, expanding ...

2022

Freenome Presents Research Highlighting the Promise of Identifying Drug-Response Biomarker for DLBCL Patients
December 12, 2022
Freenome’s comprehensive multiomics and multi-feature computational approach provides insights for therapy development and patient efficacy     SOUTH SAN FRANCISCO, Dec. 12, 2022 — Freenome, ...
Freenome Adds Several Community Partners to Clinical Study for the Early Detection of Cancer
November 1, 2022
Community-based research ensures broad reach, diversity The Vallania Study targets cancers with significant unmet needs and different care pathways SOUTH SAN FRANCISCO, Nov. 1, 2022 ...
Freenome Launches Study of Multiple Cancers Pairing Multiomics with Real-World Data
September 6, 2022
The company is pioneering a new approach for the development and improvement of its test platform by combining multiomics with real-world data  The Sanderson Study ...
Freenome Continues Growth, Adds Three New Leaders
June 2, 2022
Sally Howard, Charles Mwangi, and Julie Tran join the company to lead regulatory, finance, and people teams SOUTH SAN FRANCISCO  —  Freenome, a privately held ...
Freenome Research Underscores Clinical Utility of Screening Tests That Detect Adenomas
May 25, 2022
Research finds adenoma detection reduces mortality in colorectal cancer regardless of adherence and implementation scenarios SOUTH SAN FRANCISCO, May 25, 2022 — Freenome, a privately held ...
Freenome and Morehouse Present Research on Study Participation Among Black Patients
May 23, 2022
Study finds recruitment of Black patients at a Historically Black College or University (HBCU) matches other study sites Study receives Poster of Distinction Award at ...
Largest Clinical Study Validating a Blood-based Colorectal Screening Test Completes Enrollment
May 10, 2022
PREEMPT CRC is Freenome’s registrational study to validate its test for the early detection of cancer More than 35,000 participants enrolled and completed with a ...
Freenome and Merck KGaA, Darmstadt, Germany to Present Data on Combination of Multiomics Profiling and Computational Modeling at AACR Meeting
April 13, 2022
Signatures of non-small cell lung cancer in patients identified using Freenome’s multiomics platform SOUTH SAN FRANCISCO, April 13, 2022 — Freenome, a privately held biotech ...
Freenome Presents Research That Highlights the Significance of Detecting Adenomas in any Test That Screens for Colorectal Cancer
April 11, 2022
Cancer prevention has a greater impact than cancer interception on clinical outcomes for CRC Clinical performance requirements and diagnostic procedures vary by cancer type SOUTH ...
Lance Baldo Joins Freenome as Chief Medical Officer
April 4, 2022
Freenome, a privately held biotech company, announced today that Lance Baldo, M.D. has joined the company as chief medical officer. Dr. Baldo has more than ...
Research Highlights Changing Factors That Influence Colorectal Cancer Screening Adherence
March 15, 2022
Freenome examines thirty years of studies to understand differences in predictors of adherence across care settings Recent studies highlight increased awareness of patient environment and ...
Freenome Launches the Vallania Study for the Early Detection of Multiple Cancers
February 28, 2022
– The study targets cancers with significant unmet needs and different care pathways to optimize and streamline clinical action – Prospective study named in honor of a ...
Freenome Presents Research Highlighting its Multiomics Blood Testing Platform in PREEMPT CRC
January 24, 2022
– PREEMPT CRC Is the largest study of average risk adults for colorectal cancer  – Presentation at ASCO GI underscores innovative recruitment process for PREEMPT CRC to ...
Significant Investment Accelerates Freenome’s Multiomics Platform for the Early Detection of Cancer
January 11, 2022
Freenome surpasses $1B in total funding with major investment from Roche Freenome to expand platform to other cancers with dedicated multicancer and real-world data studies ...

2021

Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
December 7, 2021
Funding to support commercialization of blood test for colorectal cancer and expansion of platform to other cancers Freenome nears completion of enrollment for its registrational ...
Freenome Partners with Siemens Healthineers for Breast Cancer Research
December 1, 2021
Collaboration leverages imaging, diagnostic and multiomic expertise to identify new, significant biomarkers to improve the detection of breast cancer  SOUTH SAN FRANCISCO, December 1, 2021 — Freenome, ...
Morehouse School of Medicine and Freenome Present Research Demonstrating High Enrollment Rates for African Americans in Clinical Trial
October 27, 2021
– New study finds African American recruitment at a historically black college and university (HBCU) matches other patient populations – Morehouse is a leading site for enrollment ...
Freenome Shows Continued Leadership in Colorectal Cancer Research
October 25, 2021
– New research examines the benefits and burdens of adenoma detection and removal – Barriers to CRC screening need to be addressed, especially in younger adults SOUTH ...
Research Shows the Clinical Benefits of Detecting Adenomas
June 7, 2021
Freenome presented modeling findings at ASCO that demonstrate favorable outcomes in a Medicare-aged cohort SOUTH SAN FRANCISCO, June 7, 2021 — Freenome, a privately held biotech company, ...
Freenome Presents Data Revealing Signatures of Immune Checkpoint Inhibitor Treatment Response Found to Be Common Across Kidney, Melanoma, and Lung Cancers
April 10, 2021
Freenome demonstrates potential for patient stratification and monitoring using its multiomics platform at the American Association for Cancer Research (AACR) 2021 Annual Meeting SOUTH SAN ...

2020

PREEMPT CRC Trial for Blood-Based Test to Detect Colon Cancer has Expanded to Enroll Patients from Anywhere in the Continental U.S. During COVID-19 Pandemic
August 26, 2020
– COVID-19 pandemic has caused significant decline in colonoscopies and underscores the value of less invasive screening options for colorectal cancer (CRC) – Freenome is enrolling up ...
Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection
August 26, 2020
Proceeds will accelerate ongoing FDA registrational study of company’s first blood test for colorectal cancer screening and advance product pipeline Freenome will leverage its unique ...
Freenome Announces Initiation of the PREEMPT CRC Clinical Trial, a Registrational Study for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test
May 26, 2020
– Team adds Gary Reedy, CEO of the American Cancer Society, to the Board of Directors and William Quirk as Chief Financial Officer SOUTH SAN FRANCISCO, ...
Freenome Announces Encouraging Performance Data for Its Multiomics Blood Test to Detect Early-Stage Colorectal Cancer in a Prospective, Multi-Center Clinical Study
January 23, 2020
– Data to be presented at the 2020 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco SOUTH SAN FRANCISCO, Calif. — (BUSINESS ...

2019

ADC Therapeutics and Freenome Enter Biomarker Development Collaboration
August 26, 2019
– ADC Therapeutics to employ Freenome’s multiomics platform to identify biomarkers that correlate with clinical response to ADCT-402 (loncastuximab tesirine) LAUSANNE, Switzerland & SOUTH SAN ...
Freenome Closes $160 Million Series B Financing to Advance its Multiomics Blood Testing Platform for Early Cancer Detection
July 24, 2019
– Proceeds will fund pivotal validation study of company’s blood-based test for the screening of colorectal cancer – Platform has potential for use in multiple cancer types and ...
Freenome Bolsters Scientific Leadership, Naming Genomic-Medicine Pioneer, Jimmy Lin, as New Chief Scientific Officer
April 30, 2019
SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — Freenome, a leading artificial intelligence (AI) genomics company, today announced the appointment of Cheng-Ho Jimmy Lin, MD, PhD, MHS as Chief ...

2018

Freenome Unveils Promising Early Data on Colorectal Cancer Screening Test at American College of Gastroenterology Annual Meeting
October 9, 2018
PHILADELPHIA — (BUSINESS WIRE) — South San Francisco–based Freenome, the leading artificial intelligence (AI) genomics company, is presenting promising early data on its efforts to utilize ...
Freenome’s IMPACT Advisory Board Brings Strategic Insight and Real-World Experience to AI-Genomics Cancer Tests
July 12, 2018
SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — Freenome, a leading artificial intelligence (AI) genomics company, announced the creation of its IMPACT Advisory Board, a group tasked with ...
Christian Doppler Research Grant Awarded to Freenome and the Medical University of Graz to Advance Understanding of Gene Expression Changes in Cancer Using Circulating Biomarkers
June 28, 2018
SOUTH SAN FRANCISCO, Calif. & GRAZ, Austria — (BUSINESS WIRE) — Freenome and the Medical University of Graz jointly announced the launch of a new Christian ...
Freenome and Biognosys Announce Collaboration to Improve Early-Cancer Detection and Treatment
April 24, 2018
SOUTH SAN FRANCISCO, Calif. & ZURICH — (BUSINESS WIRE) — AI genomics company Freenome today announces its partnership with leading proteomics company Biognosys to enhance ...
Institut Curie and Freenome Announce a Strategic Collaboration in Cell-Free DNA Analysis Using Machine Learning Technology
March 29, 2018
PARIS & SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — Institut Curie and Freenome announce a strategic collaboration to evaluate Freenome’s artificial intelligence (AI) genomics platform as ...

2017

Invitae Chairman Randy Scott Joins Freenome Board of Directors
December 21, 2017
SAN FRANCISCO — (BUSINESS WIRE) — Freenome, a health technology company employing advanced machine learning to develop a blood test for early cancer detection, announced today that ...
Freenome Announces Formation of Scientific Advisory Board
October 18, 2017
– Inaugural members include leading experts in genomics and machine learning SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — Freenome, the health technology company creating ...
Freenome Announces Series A Extension Led by Section 32
August 28, 2017
– Section 32, founded by Bill Maris, was joined in this extension by Anne Wojcicki, co-founder of 23andMe and other Silicon Valley-based private and strategic investors ...
Freenome Appoints Abraham Tzou, M.D., Vice President, Regulatory Affairs
August 2, 2017
– Former U.S. Food and Drug Administration official will lead company’s product regulatory strategies and submissions SAN FRANCISCO — (BUSINESS WIRE) — Freenome, a health technology company reinventing disease management ...